Drug results: 1

trilaciclib Trilaciclib is a transient inhibitor of CDK 4 and 6. Hematopoietic stem and progenitor cells (HSPCs) in the bone marrow give rise to circulating neutrophils, RBCs, and platelets. HSPC proliferation is dependent on CDK4/6 activity.

Featured News

Drugcentral 2023 NAR Article

The Latest in Chemistry in Coronavirus Research

Drugs in the News

Makena Venetoclax Dapagliflozin KEYTRUDA Sacubitril LORBRENA Hydroxychloroquine

DrugCentral Search Overview